The collection of prostate biopsies into individual or site-specific specimen containers has not been performed routinely because of concerns of time, cost and lack of additional clinical value. This report evaluates the first ever use of a multicompartment microcassette for the collection and processing of site-specific prostate biopsies.
Introduction
Site-specific labelling of prostate biopsies maybe helpful in providing information on staging, deciding on excision of neurovascular bundles in radical prostatectomy, and targeting for repeat biopsies. Conventionally, site-specific biopsies are collected in individual containers and can be costly. 1 This report describes specimen collection of targeted prostate biopsies in a new multicompartmented 'microcassette', allowing easy identification of their origin, with considerable cost savings over conventional methods.
Methods
In a period of 9 months in the year 2000, 88 men referred by general practitioners underwent transrectal ultrasound (TRUS) guided biopsies of the prostate in a Central London teaching hospital. These were obtained with a disposable spring-loaded biopsy gun. At the time of biopsy, the operator placed each core of tissue obtained in an individual compartment of the microcassette (MicrosetteTM from Merck Ltd, Leics, UK). Six biopsies were taken from right side and six from the left side of the prostate. Each microcassette (Figure 1 ) holds six biopsies and individual cassettes were labelled with the patient's name and side (right, R, or left, L) of the biopsy sites. The microcassette compartments have markings from 1 to 6. A map of the biopsy sites was made on the request form, the microcassettes placed in formalin in a single specimen container, and sent to the histopathology laboratory for routine processing.
The biopsies were embedded in paraffin wax and placed numerically in order in the block. Threemicrometer sections were cut at three levels and stained with haematoxylin and eosin.
Results
TRUS-guided biopsies have been successfully processed with these cassettes in 88 cases. All have provided satisfactory results for histology. It was easy to insert each core into an individual compartment within the biopsy cassette and good quality sections in which all the tissue was seen in all cores were achieved throughout. There were 26 cancers in 88 cases (33%) of which three were less than 1 mm 3 in 12 biopsies and two were present in one core only. Small foci (less than 1 mm) of atypical glands were present in three men and five had high-grade prostatic intraepithelial neoplasia (four in association with malignancy).
Technical time is saved at various stages (Table 1) : at booking in the specimen, because there is only one container to label; no need to transfer the cores into separate biopsy cassettes; embedding only two blocks rather than 12 separate blocks; subsequent cutting of sections; and placing biopsies from each side as six on two slides rather than generating 12 slides, which also avoids having to change the slide on the microscope, with easy comparison of the cores. Overall, the time saved (average 72%) was up to 20 min per case (calculated by timing technical and consultant working).
Cost saving was calculated as follows (Table 1) : in costing for specimen containers, cassettes and slides, the overall saving for consumables is 83% per case at £3.96 vs £0.66. Storage of slides is also reduced as only two slides per case are generated.
Discussion
This is the first time that a multicompartment microcassette has been described for the acquisition and transfer of prostate biopsies with the inherent advantages of siteaccuracy, time and cost saving. Previously, site-specific biopsies could only be taken by placing each individual core in a separate pot 1 or by using different coloured dyes to identify either the side or specific origin of individual biopsies. 2 Using a microcassette as described simplifies the process, with resultant consumable and time savings in the laboratory.
Potential objections to the use of a microcassette include perceived difficulty in inserting the biopsy specimens into the individual compartment of the microcassette. The authors have not found difficulty in doing this at all. Furthermore, cores were laid out in a straight line in the same plane and it was easy to examine all parts of the specimen.
Utility of site-specific biopsies
The utility of site-specific biopsies is controversial. There is little benefit if a site-specific result does not change a management or treatment decision or provide men with information such as the chance that a nerve-sparing procedure is possible. The factor by which a test result alters the pre-test odds is known as the likelihood ratio. 3 This is unity for no change, greater than 1 for a large increase and approaches zero for a large reduction.
Extraprostatic extension
In one study, the site of biopsies from 103 men was individually identified and another 140 specimens labelled left or right. 1 Many of the biopsies were taken by external agencies. The pre-test probability (prevalence) of extraprostatic extension (EPE) was 3.5% in men with T1C cancer and rose to 11.5% (likelihood ratio 3.58) on the side of the positive biopsy and dropped to 2.5% (likelihood ratio 0.90) on the negative side. In men with a PSA < 10 ng/ml, the pre-test probability of EPE was 8% and rose to 11.4% on the side of a positive biopsy (likelihood ratio 1.40) and fell to 2.9% after a negative biopsy (likelihood ratio 0.33). The side of the biopsy was less helpful in men with T2 disease in whom the presence of cancer in Figure 1 Open microcassette containing six prostate biopsy cores and lid inferiorly. a biopsy altered only slightly the rate of EPE (14%). Perineural invasion was not analysed and this might have been informative as there are data indicating that it is more common in men with EPE. 4 The chance of EPE on the side without a positive biopsy in those with a PSA < 10 ng/ml or TlC disease was less than 3%. Men with such characteristics are forming a larger proportion of men diagnosed with prostate cancer and they may be advised that at least one neurovascular bundle may be preserved on the side without a positive biopsy with a greater chance of preserving potency. In a study in which 50% of men had T1C and 50% had T2 disease prostate cancer, the chance of EPE was reduced from 28 to 11% on the side of negative biopsy (likelihood ratio 0.32) and rose to 36% (likelihood ratio 1.44) on the side of positive biopsy (this was calculated by reanalysing Table 2 from the paper 5 ). Some of the men in this study had received neoadjuvant hormonal therapy and this might have underestimated the true extent of EPE. In this and the study by Taneja et al, 1 biopsies were taken from outside of the institution performing the radical prostatectomies and there may have been confusion over the biopsy site or mislabelling that may place doubt on their conclusions.
In one study, biopsies and radical prostatectomies were performed within the same institution and EPE was significantly associated with the side and the number of positive biopsies. 6 In their patient population (n ¼ 207), the presence of three positive biopsies raised the chance of EPE from 20 to 43% (likelihood ratio 2.86), whereas no cancer on one side reduced the chance of EPE to 8% (likelihood ratio 0.34). There was inadequate power to determine a relationship between grade of tumour and EPE.
Epstein et al 7 demonstrated that prostates were more likely to contain multifocal tumours when diagonally or horizontally sextant biopsies were malignant, but there was inadequate statistical power to show whether EPE or positive surgical margins were more common. In men with a biopsy Gleason score of 6 or less and two ipsilaterally positive cores, the organ-confined rate was 87% (14 of 16) compared with only 50% (four of eight) when contralateral cores were malignant. 8 These studies suggest that side and absence of positive biopsies might be used to determine where EPE (2% -8%) is so unlikely that excision of the neurovascular bundle will be unnecessary. More caution would be necessary on the side of positive biopsies.
Atypical glands
Repeat biopsies might be indicated in cases where a suspicion for carcinoma exists but only atypical glands are found on first biopsy. In one study, an analysis was made of sextant-to-sextant repeat biopsies performed when atypical glands were found. 2 In 46 cases in which only one atypical biopsy site was present at first biopsy, cancer was found in repeat biopsies in 48% at the same site as the initial biopsy and 85% in either the same or adjacent-sextant sites. In the 30 cases in which only one atypical biopsy site was present in the first biopsy set and one biopsy with cancer found in the second set, these were from the same site in 12 cases. As men present with earlier stage disease, more cases of atypical glands may be found and directed biopsies may increase the positive biopsy rate on repeat biopsy.
Conclusions
A new microcassette has been utilized, that allows easy collection, identification and processing of site-specific biopsies. Published data suggest that the information yielded from side-and site-specific biopsies may indicate that the chance of EPE is very low. Such knowledge may facilitate discussion on the possibility of preservation of the ipsilateral neurovascular bundle and in deciding whether intraoperative frozen sections are necessary. As men present earlier with prostate cancer, site-specific targeted biopsies might increase the positive repeat biopsy rate when atypical biopsies are found first, and distinguish between significant and insignificant cancers. The microcassette should allow collection of samples with greater accuracy and facilitate the interpretation of sitespecific biopsies from future studies in a cost-effective manner.
